Dr Rolfo talks with ecancer at the Best of ASCO 2017 meeting in Miami about new drug advancements that were presented at the ASCO annual meeting. He discusses the new NTRK inhibitor, larotrectinib, which is yielding a 76% response rate and a 12% complete...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uIrCAD
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oYRz8x via IFTTT
-
MBA Rendezvous- Read Latest Essay Topics 2016, Tips, MBA Essay Writing Strategy, Style for your Creative Essay Writing that enhance your Wri...
-
© 2011 IRA/NCTE. All rights reserved. materials may be reproduced for educational purposes. Book Review Template Let's explore some prop...
-
Shortest path problem has been a classic issue. Even more so difficulties remain involving large data environment. Current research on short...
-
by Fangzhou Li, Zhiming Feng, Peng Li, Zhen You The study of urban spatial interaction is closely linked to that of economic geography, urb...
-
Abstract Psoriasis is a multifactorial inflammatory disorder, in which the inflammation affects not only the skin but also the other inter...
-
Abstract Background Individuals with advanced, incurable cancer often experience high physical and psychological symptom burden. Family an...
-
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor British Journal of Canc...
-
Class-switch recombination (CSR) alters the Ig isotype to diversify antibody effector functions. IgD CSR is a rare event, and its regulation...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου